Trials / Conditions / Immune-related Adverse Event

Immune-related Adverse Event

20 registered clinical trials studyying Immune-related Adverse Event — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis NCT06860542	AHS Cancer Control Alberta	Phase 2
Not Yet Recruiting	Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immu NCT06908018	Mahidol University	EARLY_Phase 1
Not Yet Recruiting	Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis NCT06785974	Erasmus Medical Center	Phase 4
Recruiting	Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer NCT06613165	Xijing Hospital	—
Recruiting	Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) NCT05663775	AHS Cancer Control Alberta	Phase 2
Recruiting	SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) NCT06278857	Queensland Centre for Gynaecological Cancer	Phase 2
Recruiting	The Effect of Serum Ferritin in irAE NCT06702566	Tianjin Medical University Cancer Institute and Hospital	N/A
Recruiting	Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis NCT06037811	Tom Appleton	Phase 2
Unknown	Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events NCT06243250	Chang Gung Memorial Hospital	—
Recruiting	Food Intervention to Reduce Immunotherapy ToXicity NCT05832606	Universitair Ziekenhuis Brussel	N/A
Completed	EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigila NCT05934214	Groupe Hospitalier Pitie-Salpetriere	—
Completed	Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy NCT06089967	Duke University	—
Recruiting	Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors NCT05799898	Institut Mutualiste Montsouris	—
Terminated	Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors NCT05699915	Algemeen Ziekenhuis Maria Middelares	N/A
Recruiting	Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophen NCT05700565	Lucie Heinzerling	—
Recruiting	Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immun NCT05813418	Centre Hospitalier Universitaire, Amiens	N/A
Completed	Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negativ NCT06440811	Xijing Hospital	—
Active Not Recruiting	Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis NCT04305145	Massachusetts General Hospital	Phase 2
Completed	Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology NCT03948724	Institut Cancerologie de l'Ouest	N/A
Completed	Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors NCT05544292	Diakonhjemmet Hospital	—